Evidence map›Paper›PMID 40329202›Full record

Trial reportBMC nephrology2025

Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial.

Mohamed Mamdouh Elsayed, Marwa Ahmed Abdelrahman, Abdelrazik Mohamed Sorour, Islam Ghanem Rizk, Mohamed Aly Abdelhalim Hassab

Erratum issued Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06029179 (Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate for Treatment of Hyperkalemia in Hemodialysis Patients), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06029179 nacompletednot on this map

Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate for Treatment of Hyperkalemia in Hemodialysis Patients: A Randomized Clinical Trial

TypeinterventionalSponsorAlexandria UniversityRan2024 to 2024Enrolled120ConditionsHyperkalemiaArmssodium zirconium cyclosilicate (SZC), sodium polystyrene sulfonate
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Mohamed Mamdouh ElsayedNephrology and Internal Medicine Department, Faculty of Medicine, Alexandria University, Alkhartoom Square, El Azareeta, Alexandria, 21131, Egypt. dr_mohamedmamdouh87@yahoo.com.ORCID 0000-0001-7656-7116
Marwa Ahmed AbdelrahmanNephrology Department, Alexandria Petroleum Hospital, Alexandria, Egypt.
Abdelrazik Mohamed SorourNephrology Department, Alexandria Petroleum Hospital, Alexandria, Egypt.
Islam Ghanem RizkNephrology and Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.
Mohamed Aly Abdelhalim HassabNephrology and Internal Medicine Department, Medical Research Institute, Alexandria University, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperkalemia is a frequent life-threatening condition in hemodialysis (HD) patients. Data comparing the usage of various K + binders in HD patients is still scarce. This study aimed to compare the efficacy and safety of Sodium zirconium cyclosilicate (SZC) and sodium polystyrene sulfonate (SPS) for treatment of hyperkalemia in HD patients.

methodsThis prospective, double-blinded, randomized multicenter clinical trial enrolled 120 HD patients with predialysis serum potassium > 5 mmol/L. Patients were randomized to receive SZC (5 g, 3 times/wk on non-dialysis days, 15 gm/wk) or SPS (15 g, 3 times/wk on non-dialysis days, 45 gm/wk) for 8 weeks. The change in serum potassium through the 8 weeks of the study was our primary outcome.

resultsSerum potassium significantly decreased in both groups compared to baseline values from the first week till the end of the study with p value of < 0.001 and < 0.001 respectively. Serum K levels in the SZC group were significantly lower (achieved normokalemia after 2 weeks) than K levels in the SPS group (achieved normokalemia after 6 weeks) through the study period (p < 0.001). Rescue therapy for hyperkalemia was less frequent in the SZC group (3.3%) than the SPS group (6.6%) (p = 0.678). Gastrointestinal side effects were non significantly fewer with SZC (5%) compared to SPS (11.6%). However, SPS was less palatable (p < 0.001).

conclusionsWhen compared to SPS treatment, SZC was associated with a more rapid and efficacious resolution of hyperkalemia with potentially a better safety profile and palatability among HD patients. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier: NCT06029179. First registration date: 9/01/2023.

Indexed as

HyperkalemiaPolystyrenesRenal DialysisSilicatesAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedPotassiumProspective StudiesTreatment OutcomePolystyrenespolystyrene sulfonic acidPotassiumSilicatessodium zirconium cyclosilicateHemodialysisHyperkalemiaSodium polystyrene sulfonateSodium zirconium cyclosilicate

Identifiers

PMID40329202
PMCPMC12054224

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.